ГЕНДЕРНЫЕ ХАРАКТЕРИСТИКИ НЕГАТИВНОЙ СИМПТОМАТИКИ И ФУНКЦИОНАЛЬНОГО ИСХОДА У ПАЦИЕНТОВ С ШИЗОФРЕНИЕЙ
Обзорная статья
Дата публикации: сентября 4, 2023
Ключевые слова
шизофрения
функциональный исход
негативная симптоматика
функциональный исход
негативная симптоматика
Как цитировать
Петрова Н. Н., Манюшина В. М. ГЕНДЕРНЫЕ ХАРАКТЕРИСТИКИ НЕГАТИВНОЙ СИМПТОМАТИКИ И ФУНКЦИОНАЛЬНОГО ИСХОДА У ПАЦИЕНТОВ С ШИЗОФРЕНИЕЙ // Кремлевская медицина. Клинический вестник. 2023. Т. № 3. С. 96-100.
Аннотация
Приведен нарративный обзор литературы, осуществленный в системах PubМed и Google. Использованы ключевые слова: шизофрения, функциональный исход, негативная симптоматика, гендер. Критерии включения: рандомизированные клинические исследования, метаанализы и систематические обзоры, релевантные полнотекстовые статьи. Критерии исключения: статьи низкого качества. Терминология статьи соответствует используемой во включенных в обзор публикациях. В статье проанализированы представления о негативной симптоматике и исходах шизофрении, приведены гендерные различия негативной симптоматики и функционирования пациентов с шизофренией, сделан вывод о том, что учет гендерных особенностей заболевания будет способствовать оптимизации функционального исхода заболевания.Литература
1. Швец К.Н. и др. Факторы социальной дезадаптации больных шизофренией и подходы к психосоциальной терапии и реабилитации // Научные результаты биомедицинских исследований. – 2019. – Т. 2. – С. 72–85. [Shvets K.N., Khamskaya I.S. Factors of social maladaptation of patients with schizophrenia and approaches to psychosocial therapy and rehabilitation // Scientific results of biomedical research. – 2019. – V. 2. – P. 72–85. In Russian].
2. Ерзин А.И. и др. Взаимосвязь негативной симптоматики и проактивности у больных с первым эпизодом шизофрении // Социальная и клиническая психиатрия. – 2015. – Т. 4. – С. 5–8. [Yerzin A.I. et al. The relationship of negative symptoms and reactivity in patients with the first episode of schizophrenia // Social and Clinical Psychiatry. – 2015. – V. 4. – P. 5-8. In Russian].
3. Unrau J. et al. Subtyping negative symptoms in first-episode psychosis: сontrasting persistent negative symptoms with a data-driven approach // Schizophr Res. – 2022. – № 248. – Р. 219–227. doi: 10.1016/j.schres.2022.09.010.
4. Puig O. et al. Persistent negative symptoms in first-episode psychosis: early cognitive and social functioning correlates and differences between early and adult onset psychiatry // J Clin Psychiatry. – 2017. – V. 78. – № 9. – P. 1414–1422. doi: 10.4088/JCP.16m1112.
5. Wójciak P. et al. Clinical picture, pathogenesis and psychometric assessment of negative symptoms of schizophrenia // Psychiatr Pol. – 2018. – V. 52. – № 2. – Р. 185–197. doi: 10.12740/PP/70610.
6. Петрова Н.Н. К вопросу о гетерогенности негативной симптоматики при шизофрении // Социальная и клиническая психиатрия. – 2020. – Т. 1. – С. 81–86. [Petrova N.N. On the heterogeneity of negative symptoms in schizophrenia // Social and clinical psychiatry. – 2020. – V. 1. – P. 81–86. In Russian].
7. Thande N.K. et al. The influence of sex and gender on health: how much is being taught in medical school curricula? // J Women's Health. – 2019. – V. 28 – № 12. – Р. 1748–1754. doi: 10.1089/jwh.2018.7229.
8. Li X. et al. A glimpse of gender differences in schizophrenia // General psychiatry. – 2022. – V. 35. – № 4. doi: 10.1136/gpsych-2022-100823.
9. Giordano G.M. et al. Gender differences in clinical and psychosocial features among persons with schizophrenia: a mini review // Front Psychiatry. – 2021. – V. 12. – Art. 789179. doi: 10.3389/fpsyt.2021.789179
10. Riecher-Rössler A. Sex and gender differences in mental disorders // The Lancet Psychiatry. – 2017. – V. 4. – № 1. – Р. 8–9. doi: 10.1016/S2215-0366 (16)30348-0.
11. Zorkina Y. et al. Sex differences in social functioning of patients with schizophrenia depending on the age of onset and severity of the disease // Early Interv Psychiatry. – 2021. – V. 15. – № 5. – P. 1197–1209. doi: 10.1111/eip.13063.
12. Quattrone D. et al. Transdiagnostic dimensions of psychopathology at first episode psychosis: findings from the multinational EU-GEI study // Psycho Med. – 2019. – V. 49. – № 8. – P. 1378–1391. doi: 10.1017/S0033291718002131.
13. Muralidharan A. et al. Older versus middle-aged adults with schizophrenia: executive functioning and community outcomes // Schizophr Res. – 2020. – V. 216. – P. 547–549. doi: 10.1016/j.schres.2019.11.001.
14. Grau N. et al. Influence of cognition, premorbid adjustment and psychotic symptoms on psycho-socialfunctioning in first-episode // Psychiatry Res. – 2016. – V. 242 – P. 157–162. doi: 10.1016/j.psychres.2016.04.121.
15. Harvey P.D. et al. Associations of age and gender with negative symptom factors and functioning among middle-aged and older adults with schizophren // Am J Geriatr Psychiatry. –2018. – V. 26. – № 12. – P. 1215–1219. doi: 10.1016/j.jagp.2018.07.006.
16. Strauss G.P. et al. Deconstructing negative symptoms of schizophrenia: avolition-apathy and diminished expression clusters predict clinical presentation and functional outcome // Am J Geriatr Psychiatry. – 2013. – V. 47. – № 6. – P. 783–790. doi: 10.1016/j.jagp.2018.07.006.
17. Wojciak P. et al. Negative symptoms in schizophrenia, assessed by the brief negative symptom scale, self-evaluation of negative symptom scale, and social cognition: a gender effect // Int J Psychiatry Clin Pract. – 2021. – V. 25. – P. 252–257. doi: 10.1080/13651501.2020.18102.
18. Charernboon T. et al. Social cognition in schizophrenia // Ment Ill. – 2017. – V. 9. – № 1. – P. 16–19. doi: 10.4081/mi.2017.7054.
19. Navarra-Ventura G. et al. Gender differences in social cognition: a cross-sectional pilot study of recently diagnosed patients with schizophrenia and healthy subjects // Can J Psychiatry. – 2018. – V. 63. – № 8. – P. 538–546. doi: 10.1177/0706743717746661.
20. Thibaudeau E. et al. Functional impairments and theory of mind deficits in schizophrenia: a meta-analysis of the associations // Schizophr Bull. – 2021. – V. 47. – № 3. – P. 695–711. doi: 10.1093/schbul/sbaa182.
21. Захаров Н.Б. и др. Гендерный фактор и психические расстройства // Вятский медицинский вестник. – 2022. – Т. 3. – С. 77–81. [Zakharov N.B. et al. Gender factor and mental disorders // Vyatka Medical Bulletin. – 2022. – V. 3. – P. 77–81. In Russian].
22. Jaaskelainen E. et al. A systematic review and meta-analysis of recovery in schizophrenia // Schizophr Bull. – 2013 – V. 39. – P.1296–306. doi: 10.1093/schbul/sbs130.
23. Seeman M.V. Does gender influence outcome in schizophrenia? // Psychiat Q. – 2019. – V. 90. – № 1. – P. 173–184. doi: 10.1007/s11126-018-9619-y.
24. Heckers S. et al. The evolution of Kraepelin's nosological principles // World Psychiatry. –2020. – V. 19. – P. 381–388. doi: 10.1002/wps.20774.
25. Keefe R.S.E. Why are there no approved treatments for cognitive impairment in schizophrenia? // World Psychiatry. – 2019. – V. 18. – P. 167–178. doi: 10.1002/wps.2064.
26. Mier D. Social-cognitive deficits in schizophrenia // Curr Top Behave Neurosci. – 2017. – V. 30. – P. 397–409. doi: 10.1007/7854_2015_427.
27. Harvey P.D. et al. Cognition and disability in schizophrenia: cognition-related skills deficits and decision-making challenges add to morbidity // World Psychiatry. – 2019. – V. 18. – P. 165–167. doi: 10.1002/wps.20647.
28. Oakley P. et al. Increased mortality among people with schizophrenia and other non-affective psychotic disorders in the community: a systematic review and meta-analysis // J Psychiat Res. – 2018. – V. 103. – P. 245–253. doi: 10.1016/j.jpsychires.2018.04.019.
29. Plana-Ripoll O. et al. Nature and prevalence of combinations of mental disorders and their association with excess mortality in a population-based cohort study // World Psychiatry. – 2020. – V. 19. – P. 339–349. doi: 10.1002/wps.20802.
30. Sommer I.E. et al. The clinical course of schizophrenia in women and men-a nation-wide cohort study // NPJ Schizophr. – 2020. – V. 6. – № 1. – P. 12. doi: 10.1038/s41537-020-0102-z.
31. Taipale H. et al. 20-year follow-up study of physical morbidity and mortality in relationship to antipsychotic treatment in a nationwide cohort of 62 250 patients with schizophrenia // World Psychiatry. – 2020. – V. 19. – P. 61–68. doi: 10.1002/wps.20699.
32. Goodsmith N. et al. Predictors of functioning and recovery among men and women veterans with schizophrenia // Community Ment Health J. – 2023. – V. 59. – №1. – P. 110–121. doi: 10.1007/s10597-022-00979-x
33. Thorup A. et al. Gender differences in first-episode psychosis at 5-year follow-up–two different courses of disease? Results from the OPUS study at 5-year followup // Eur Psychiatry. – 2014. – V. 29. – P. 44–51. doi: 10.1016/j.eurpsy.2012.11.005.
34. Bouwmans C. et al. Employment and the associated impact on quality of life in people diagnosed with schizophrenia // Neuropsychiatr Dis Treat. – 2015. – V. 11. – P. 2125–2142. doi: 10.2147/NDT.S83546.
35. Gupta T. et al. Deconstructing 2symptoms in individuals at clinical high-risk for psychosis: evidence for volitional and diminished emotionality subgroups that predict clinical presentation and functional outcome // schizophr Bulletin. – 2021. – V. 47. – P. 54–63. doi: 10.1093/schbul/sbaa084.
36. Strauss G.P. et al. Network analysis reveals which negative symptom domains are most central in schizophrenia vs bipolar disorder // Schizophr Bulletin. – 2019. – V. 45. – P. 1319–1330. doi: 10.1093/schbul/sby168.
37. Favrod J. et al. Improving pleasure and motivation in schizophrenia: a randomized controlled clinical trial // Psychother Psychosom. – 2019 – V. 88. – P. 84–95. doi: 10.1159/000496479.
38. Cohen A.S. et al. Using biobehavioral technologies to effectively advance research on negative symptoms. Using biobehavioral technologies to effectively advance research on negative symptoms // World psychiatry. – 2019. –V. 18. – P. 103–104. doi: 10.1002/wps.20593.
39. Dama M. et al. Sex differences in clinical and functional outcomes among patients treated in an early intervention service for psychotic disorders: an observational study // Can J Psychiatry. – 2019 –V. 64. – P.708–717. doi: 10.1177/0706743719854069.
40. Estancial F. et al. Psycho-tropic use patterns: are there differences between men and women? // PLOS One. – 2018. – V. 13. – P. 11–14. DOI: 10.1371/journal.pone.0207921.
41. Hanlon M.C. et al. Men and women with psychosis and the impact of illness-duration on sex-differences: the second Australian national survey of psychosis // Psychiatry Res. – 2017. – V. 256. – P. 130–143. doi: 10.1016/j.psychres.2017.06.0242017.
42. Петрова Н.Н. и др. Половые особенности первого эпизода шизофрении // Психическое здоровье. – 2018. – Т. 5. – С. 43–51. [Petrova N.N. et al. Sexual characteristics of the first episode of schizophrenia // Mental health. – 2018. – V. 5. – P. 43–51. In Russian].
43. Bottlender R. et al. Social disability in schizophrenic, schizoaffective and affective disorders 15 years after first admission // Schizophr research. – 2010. – V. 116. – № 1. – P. 9–15. doi: 10.1016/j.schres.2009.10.008.
44. Dubreucq M. et al. Sex differences in recovery-related outcomes and needs for psychiatric rehabilitation in people with schizophrenia spectrum disorder // J Clin Psychiatry. – 2021. –V. 82. № 4. – P. 395–408. doi: 10.4088/JCP.20m13732.
45. Thara R. et al. Women and schizophrenia // Ind J Psychiatry. – 2015. – V. 57. – № 2. – P. 246–251. doi: 10.4103/0019-5545.161487.
46. Novick D. et al. Sex differences in the course of schizophrenia across diverse regions of the world // Neuropsychiatr Dis Treat. – 2016. – V. 12. – P. 2927–2939. doi: 10.2147/NDT.S101151.
47. Lee E.E. et al. A widening longevity gap between people with schizophrenia and general population: a literature review and call for action // Schizophr research. – 2018. – V. 196. –P. 9–13. doi: 10.1016/j.schres.2017.09.005.
48. Firmin R.L. et al. How psychosis interrupts the lives of women and men differently: a qualitative comparison // Psychol Psychother. – 2021. – V. 94. – № 3. – P. 704–720. doi: 10.1111/papt.12317.
49. Prat G. et al. Gender differences in social functioning in people with schizophrenia in psychosocial rehabilitation services using one-dimensional and multidimensional instruments // Compr Psychiatry. – 2018. – V. 87. – P. 120–122. doi: 10.1016/j.comppsych.2018.10.004.
50. Vázquez-Reyes A. et al. Ten-year follow-up of social functioning and behaviour problems in people with schizophrenia and related disorders // Int. J. Soc. Psychiat. – 2022. – V. 68. – № 7. – P. 1324–1335. doi: 10.1177/0020764021102308.
51. Петрова Н.Н. Выздоровление при шизофрении: роль современных инъекционных антипсихотиков-пролонгов // Современная терапия психических расстройств. – 2022. – Т. 2. – С. 44–52. [Petrova N.N. Recovery in schizophrenia: the role of modern injectable antipsychotics-prolongs // Modern therapy of mental disorders. – 2022. – V. 2. – P. 44–52. In Russian].
52. Johnston M. et al. Redefining outcome measures in schizophrenia: integrating social and clinical parameters // Curr Opin Psychiatry. – 2010. – V. 23. – № 2. – P. 120–126. doi: 10.1097/YCO.0b013e328336662e.
53. Chan R. et al. Flourishing with psychosis: a prospective examination on the interactions between clinical, functional, and personal recovery processes on well-being among individuals with schizophrenia spectrum disorders // Schizophr Bull. – 2018. – V. 44. – № 4. – P. 778–786. doi: 10.1093/schbul/sbx120.
54. Leonhardt B.L. et al. Recovery and serious mental illness: a review of current clinical and research paradigms and future directions. Exp Rev Neurother. – 2017. – V. 17. – № 11. – P. 1117–1130. doi: 10.1080/14737175.2017.1378099.
55. Gardsjord E.S. et al. Is going into stable symptomatic remission associated with a more positive development of life satisfaction? A 10-year follow-up study of first episode psychosis. Schizophr Res. – 2018. – V. 193. – P. 364–369.
56. Fond G. et al. Remission of depression in patients with schizophrenia and comorbid major depressive disorder: results from the FACE-SZ cohort // Br J Psychiat. – 2018. – V. 213. – № 2. – P. 464–470. doi: 10.1192/bjp.2018.87.
57. Van E.R. et al. The relationship between clinical and personal recovery in patients with schizophrenia spectrum disorders: a systematic review and meta-analysis. Schizophr bulletin. – 2018. – V. 44. – № 3. – P. 631–642. doi: 10.1093/schbul/sbx088.
58. Fond G. et al. Depressive symptoms and chronic peripheral inflammation are associated with impaired functional remission in schizophrenia independently of psychotic remission. J Affect Disord. – 2021. – V. 280. – P. 267–271. doi: 10.1016/j.jad.2020.11.046.
59. Dubreucq J. et al. RemedRugby Group. Improving social function with real-world social-cognitive remediation in schizophrenia: results from the RemedRugby quasi-experimental trial // Eur Psychiatry. – 2020. – V. 63. – № 1. doi: 10.1192/j.eurpsy.2020.
60. Mayston R. et al. The effect of gender on the long-term course and outcome of schizophrenia in rural Ethiopia: a population-based cohort // Soc Psychiatry and Psychiatr Epidemiol. – 2020. – V. 55. P. 1581–1591.
2. Ерзин А.И. и др. Взаимосвязь негативной симптоматики и проактивности у больных с первым эпизодом шизофрении // Социальная и клиническая психиатрия. – 2015. – Т. 4. – С. 5–8. [Yerzin A.I. et al. The relationship of negative symptoms and reactivity in patients with the first episode of schizophrenia // Social and Clinical Psychiatry. – 2015. – V. 4. – P. 5-8. In Russian].
3. Unrau J. et al. Subtyping negative symptoms in first-episode psychosis: сontrasting persistent negative symptoms with a data-driven approach // Schizophr Res. – 2022. – № 248. – Р. 219–227. doi: 10.1016/j.schres.2022.09.010.
4. Puig O. et al. Persistent negative symptoms in first-episode psychosis: early cognitive and social functioning correlates and differences between early and adult onset psychiatry // J Clin Psychiatry. – 2017. – V. 78. – № 9. – P. 1414–1422. doi: 10.4088/JCP.16m1112.
5. Wójciak P. et al. Clinical picture, pathogenesis and psychometric assessment of negative symptoms of schizophrenia // Psychiatr Pol. – 2018. – V. 52. – № 2. – Р. 185–197. doi: 10.12740/PP/70610.
6. Петрова Н.Н. К вопросу о гетерогенности негативной симптоматики при шизофрении // Социальная и клиническая психиатрия. – 2020. – Т. 1. – С. 81–86. [Petrova N.N. On the heterogeneity of negative symptoms in schizophrenia // Social and clinical psychiatry. – 2020. – V. 1. – P. 81–86. In Russian].
7. Thande N.K. et al. The influence of sex and gender on health: how much is being taught in medical school curricula? // J Women's Health. – 2019. – V. 28 – № 12. – Р. 1748–1754. doi: 10.1089/jwh.2018.7229.
8. Li X. et al. A glimpse of gender differences in schizophrenia // General psychiatry. – 2022. – V. 35. – № 4. doi: 10.1136/gpsych-2022-100823.
9. Giordano G.M. et al. Gender differences in clinical and psychosocial features among persons with schizophrenia: a mini review // Front Psychiatry. – 2021. – V. 12. – Art. 789179. doi: 10.3389/fpsyt.2021.789179
10. Riecher-Rössler A. Sex and gender differences in mental disorders // The Lancet Psychiatry. – 2017. – V. 4. – № 1. – Р. 8–9. doi: 10.1016/S2215-0366 (16)30348-0.
11. Zorkina Y. et al. Sex differences in social functioning of patients with schizophrenia depending on the age of onset and severity of the disease // Early Interv Psychiatry. – 2021. – V. 15. – № 5. – P. 1197–1209. doi: 10.1111/eip.13063.
12. Quattrone D. et al. Transdiagnostic dimensions of psychopathology at first episode psychosis: findings from the multinational EU-GEI study // Psycho Med. – 2019. – V. 49. – № 8. – P. 1378–1391. doi: 10.1017/S0033291718002131.
13. Muralidharan A. et al. Older versus middle-aged adults with schizophrenia: executive functioning and community outcomes // Schizophr Res. – 2020. – V. 216. – P. 547–549. doi: 10.1016/j.schres.2019.11.001.
14. Grau N. et al. Influence of cognition, premorbid adjustment and psychotic symptoms on psycho-socialfunctioning in first-episode // Psychiatry Res. – 2016. – V. 242 – P. 157–162. doi: 10.1016/j.psychres.2016.04.121.
15. Harvey P.D. et al. Associations of age and gender with negative symptom factors and functioning among middle-aged and older adults with schizophren // Am J Geriatr Psychiatry. –2018. – V. 26. – № 12. – P. 1215–1219. doi: 10.1016/j.jagp.2018.07.006.
16. Strauss G.P. et al. Deconstructing negative symptoms of schizophrenia: avolition-apathy and diminished expression clusters predict clinical presentation and functional outcome // Am J Geriatr Psychiatry. – 2013. – V. 47. – № 6. – P. 783–790. doi: 10.1016/j.jagp.2018.07.006.
17. Wojciak P. et al. Negative symptoms in schizophrenia, assessed by the brief negative symptom scale, self-evaluation of negative symptom scale, and social cognition: a gender effect // Int J Psychiatry Clin Pract. – 2021. – V. 25. – P. 252–257. doi: 10.1080/13651501.2020.18102.
18. Charernboon T. et al. Social cognition in schizophrenia // Ment Ill. – 2017. – V. 9. – № 1. – P. 16–19. doi: 10.4081/mi.2017.7054.
19. Navarra-Ventura G. et al. Gender differences in social cognition: a cross-sectional pilot study of recently diagnosed patients with schizophrenia and healthy subjects // Can J Psychiatry. – 2018. – V. 63. – № 8. – P. 538–546. doi: 10.1177/0706743717746661.
20. Thibaudeau E. et al. Functional impairments and theory of mind deficits in schizophrenia: a meta-analysis of the associations // Schizophr Bull. – 2021. – V. 47. – № 3. – P. 695–711. doi: 10.1093/schbul/sbaa182.
21. Захаров Н.Б. и др. Гендерный фактор и психические расстройства // Вятский медицинский вестник. – 2022. – Т. 3. – С. 77–81. [Zakharov N.B. et al. Gender factor and mental disorders // Vyatka Medical Bulletin. – 2022. – V. 3. – P. 77–81. In Russian].
22. Jaaskelainen E. et al. A systematic review and meta-analysis of recovery in schizophrenia // Schizophr Bull. – 2013 – V. 39. – P.1296–306. doi: 10.1093/schbul/sbs130.
23. Seeman M.V. Does gender influence outcome in schizophrenia? // Psychiat Q. – 2019. – V. 90. – № 1. – P. 173–184. doi: 10.1007/s11126-018-9619-y.
24. Heckers S. et al. The evolution of Kraepelin's nosological principles // World Psychiatry. –2020. – V. 19. – P. 381–388. doi: 10.1002/wps.20774.
25. Keefe R.S.E. Why are there no approved treatments for cognitive impairment in schizophrenia? // World Psychiatry. – 2019. – V. 18. – P. 167–178. doi: 10.1002/wps.2064.
26. Mier D. Social-cognitive deficits in schizophrenia // Curr Top Behave Neurosci. – 2017. – V. 30. – P. 397–409. doi: 10.1007/7854_2015_427.
27. Harvey P.D. et al. Cognition and disability in schizophrenia: cognition-related skills deficits and decision-making challenges add to morbidity // World Psychiatry. – 2019. – V. 18. – P. 165–167. doi: 10.1002/wps.20647.
28. Oakley P. et al. Increased mortality among people with schizophrenia and other non-affective psychotic disorders in the community: a systematic review and meta-analysis // J Psychiat Res. – 2018. – V. 103. – P. 245–253. doi: 10.1016/j.jpsychires.2018.04.019.
29. Plana-Ripoll O. et al. Nature and prevalence of combinations of mental disorders and their association with excess mortality in a population-based cohort study // World Psychiatry. – 2020. – V. 19. – P. 339–349. doi: 10.1002/wps.20802.
30. Sommer I.E. et al. The clinical course of schizophrenia in women and men-a nation-wide cohort study // NPJ Schizophr. – 2020. – V. 6. – № 1. – P. 12. doi: 10.1038/s41537-020-0102-z.
31. Taipale H. et al. 20-year follow-up study of physical morbidity and mortality in relationship to antipsychotic treatment in a nationwide cohort of 62 250 patients with schizophrenia // World Psychiatry. – 2020. – V. 19. – P. 61–68. doi: 10.1002/wps.20699.
32. Goodsmith N. et al. Predictors of functioning and recovery among men and women veterans with schizophrenia // Community Ment Health J. – 2023. – V. 59. – №1. – P. 110–121. doi: 10.1007/s10597-022-00979-x
33. Thorup A. et al. Gender differences in first-episode psychosis at 5-year follow-up–two different courses of disease? Results from the OPUS study at 5-year followup // Eur Psychiatry. – 2014. – V. 29. – P. 44–51. doi: 10.1016/j.eurpsy.2012.11.005.
34. Bouwmans C. et al. Employment and the associated impact on quality of life in people diagnosed with schizophrenia // Neuropsychiatr Dis Treat. – 2015. – V. 11. – P. 2125–2142. doi: 10.2147/NDT.S83546.
35. Gupta T. et al. Deconstructing 2symptoms in individuals at clinical high-risk for psychosis: evidence for volitional and diminished emotionality subgroups that predict clinical presentation and functional outcome // schizophr Bulletin. – 2021. – V. 47. – P. 54–63. doi: 10.1093/schbul/sbaa084.
36. Strauss G.P. et al. Network analysis reveals which negative symptom domains are most central in schizophrenia vs bipolar disorder // Schizophr Bulletin. – 2019. – V. 45. – P. 1319–1330. doi: 10.1093/schbul/sby168.
37. Favrod J. et al. Improving pleasure and motivation in schizophrenia: a randomized controlled clinical trial // Psychother Psychosom. – 2019 – V. 88. – P. 84–95. doi: 10.1159/000496479.
38. Cohen A.S. et al. Using biobehavioral technologies to effectively advance research on negative symptoms. Using biobehavioral technologies to effectively advance research on negative symptoms // World psychiatry. – 2019. –V. 18. – P. 103–104. doi: 10.1002/wps.20593.
39. Dama M. et al. Sex differences in clinical and functional outcomes among patients treated in an early intervention service for psychotic disorders: an observational study // Can J Psychiatry. – 2019 –V. 64. – P.708–717. doi: 10.1177/0706743719854069.
40. Estancial F. et al. Psycho-tropic use patterns: are there differences between men and women? // PLOS One. – 2018. – V. 13. – P. 11–14. DOI: 10.1371/journal.pone.0207921.
41. Hanlon M.C. et al. Men and women with psychosis and the impact of illness-duration on sex-differences: the second Australian national survey of psychosis // Psychiatry Res. – 2017. – V. 256. – P. 130–143. doi: 10.1016/j.psychres.2017.06.0242017.
42. Петрова Н.Н. и др. Половые особенности первого эпизода шизофрении // Психическое здоровье. – 2018. – Т. 5. – С. 43–51. [Petrova N.N. et al. Sexual characteristics of the first episode of schizophrenia // Mental health. – 2018. – V. 5. – P. 43–51. In Russian].
43. Bottlender R. et al. Social disability in schizophrenic, schizoaffective and affective disorders 15 years after first admission // Schizophr research. – 2010. – V. 116. – № 1. – P. 9–15. doi: 10.1016/j.schres.2009.10.008.
44. Dubreucq M. et al. Sex differences in recovery-related outcomes and needs for psychiatric rehabilitation in people with schizophrenia spectrum disorder // J Clin Psychiatry. – 2021. –V. 82. № 4. – P. 395–408. doi: 10.4088/JCP.20m13732.
45. Thara R. et al. Women and schizophrenia // Ind J Psychiatry. – 2015. – V. 57. – № 2. – P. 246–251. doi: 10.4103/0019-5545.161487.
46. Novick D. et al. Sex differences in the course of schizophrenia across diverse regions of the world // Neuropsychiatr Dis Treat. – 2016. – V. 12. – P. 2927–2939. doi: 10.2147/NDT.S101151.
47. Lee E.E. et al. A widening longevity gap between people with schizophrenia and general population: a literature review and call for action // Schizophr research. – 2018. – V. 196. –P. 9–13. doi: 10.1016/j.schres.2017.09.005.
48. Firmin R.L. et al. How psychosis interrupts the lives of women and men differently: a qualitative comparison // Psychol Psychother. – 2021. – V. 94. – № 3. – P. 704–720. doi: 10.1111/papt.12317.
49. Prat G. et al. Gender differences in social functioning in people with schizophrenia in psychosocial rehabilitation services using one-dimensional and multidimensional instruments // Compr Psychiatry. – 2018. – V. 87. – P. 120–122. doi: 10.1016/j.comppsych.2018.10.004.
50. Vázquez-Reyes A. et al. Ten-year follow-up of social functioning and behaviour problems in people with schizophrenia and related disorders // Int. J. Soc. Psychiat. – 2022. – V. 68. – № 7. – P. 1324–1335. doi: 10.1177/0020764021102308.
51. Петрова Н.Н. Выздоровление при шизофрении: роль современных инъекционных антипсихотиков-пролонгов // Современная терапия психических расстройств. – 2022. – Т. 2. – С. 44–52. [Petrova N.N. Recovery in schizophrenia: the role of modern injectable antipsychotics-prolongs // Modern therapy of mental disorders. – 2022. – V. 2. – P. 44–52. In Russian].
52. Johnston M. et al. Redefining outcome measures in schizophrenia: integrating social and clinical parameters // Curr Opin Psychiatry. – 2010. – V. 23. – № 2. – P. 120–126. doi: 10.1097/YCO.0b013e328336662e.
53. Chan R. et al. Flourishing with psychosis: a prospective examination on the interactions between clinical, functional, and personal recovery processes on well-being among individuals with schizophrenia spectrum disorders // Schizophr Bull. – 2018. – V. 44. – № 4. – P. 778–786. doi: 10.1093/schbul/sbx120.
54. Leonhardt B.L. et al. Recovery and serious mental illness: a review of current clinical and research paradigms and future directions. Exp Rev Neurother. – 2017. – V. 17. – № 11. – P. 1117–1130. doi: 10.1080/14737175.2017.1378099.
55. Gardsjord E.S. et al. Is going into stable symptomatic remission associated with a more positive development of life satisfaction? A 10-year follow-up study of first episode psychosis. Schizophr Res. – 2018. – V. 193. – P. 364–369.
56. Fond G. et al. Remission of depression in patients with schizophrenia and comorbid major depressive disorder: results from the FACE-SZ cohort // Br J Psychiat. – 2018. – V. 213. – № 2. – P. 464–470. doi: 10.1192/bjp.2018.87.
57. Van E.R. et al. The relationship between clinical and personal recovery in patients with schizophrenia spectrum disorders: a systematic review and meta-analysis. Schizophr bulletin. – 2018. – V. 44. – № 3. – P. 631–642. doi: 10.1093/schbul/sbx088.
58. Fond G. et al. Depressive symptoms and chronic peripheral inflammation are associated with impaired functional remission in schizophrenia independently of psychotic remission. J Affect Disord. – 2021. – V. 280. – P. 267–271. doi: 10.1016/j.jad.2020.11.046.
59. Dubreucq J. et al. RemedRugby Group. Improving social function with real-world social-cognitive remediation in schizophrenia: results from the RemedRugby quasi-experimental trial // Eur Psychiatry. – 2020. – V. 63. – № 1. doi: 10.1192/j.eurpsy.2020.
60. Mayston R. et al. The effect of gender on the long-term course and outcome of schizophrenia in rural Ethiopia: a population-based cohort // Soc Psychiatry and Psychiatr Epidemiol. – 2020. – V. 55. P. 1581–1591.